Are you ready to transform your patent practice?
Patent prosecution is complex – we know. If you’re ready for simpler workflows and more predictable outcomes, give us a call.
(gradient)+(2).png?width=2188&height=463&name=Juristat_Primary+(white+text)(gradient)+(2).png "Juristat | Patent analytics & workflow automation")
(gradient).png?width=2188&height=463&name=Juristat_Primary+(grey+text)(gradient).png "Juristat | Patent analytics & workflow automation")
Clarissa Clinton
Highlights From the USPTO's Study of COVID-19 Diagnostic Patents
The COVID-19 pandemic launched a healthcare innovation race without parallel in recent history. Recognizing the need for swift action, companies large and small across the healthcare industry jumped into action to do their part to develop diagnostics, therapeutics, and vaccines for COVID-19. Now that roughly two years have passed since the peak of the pandemic, we have a fuller body of COVID-19-related patenting data from the USPTO and patent offices around the world. While several studies have analyzed COVID-19-related patents — notably, the WIPO 2022 study of COVID-19 vaccines and therapeutics — none have focused specifically on COVID-19 diagnostics patents.